Frazier Lifesciences Acquisition Corporation

General Information

We intend to capitalize on the ability of our management team to identify promising opportunities in the biotechnology sector.

Our sponsor, Frazier Lifesciences Sponsor LLC, is an affiliate of Frazier Healthcare Partners (“Frazier”), founded in 1991 as one of the first healthcare dedicated investment firms, with nearly $4.8 billion raised across 12 institutional funds. From 2005 to present, under the leadership of Managing General Partners Patrick Heron and James (“Jamie”) Topper, the Frazier Life Sciences team has focused exclusively on life sciences companies and has deployed over $1.2 billion of capital into the life sciences sector with a focus on investing in and creating industry leading biopharmaceutical companies. With its broad range of private and public investment activity and company founding efforts, the Frazier Life Sciences portfolio has brought to market 30 new drugs over the past decade.

(Note: The Frazier Lifesciences Acquisition Corp. IPO was upsized at pricing: 12 million units (vs. 10 million in the prospectus) were priced at $10 each.) 

Employees: 0
Founded: 2020
Contact Information
Address Two Union Square 601 Union St., Suite 3200 Seattle, WA 98101
Phone Number +1 (206) 621-7200
Web Address
View Prospectus: Frazier Lifesciences Acquisition Corporation
Financial Information
Market Cap $149.25mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol FLACU
Exchange NASDAQ
Shares (millions): 12.0
Price range $10.00 - $10.00
Est. $ Volume $120.0 mil
Manager / Joint Managers Credit Suisse
CO-Managers -
Expected To Trade: 12/9/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change